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Abstract 
Perfluorooctanesulfonic acid (PFOS) is a persistent, toxic fluorosurfactant foam 
used in firefighting foams, textiles, and other industrial products. Human CYP2B6 is 
predominantly expressed in the liver and responsible for metabolizing xeno- and 
endobiotics. CYP2B is induced by PFOS and high-fat diets in rodents and therefore it 
was hypothesized that CYP2B contributed to PFOS-induced steatosis. Cyp2b-9/10/13-
null (Cyp2b-null) and humanized CYP2B6-Tg (hCYP2B6-Tg) mice were treated with 
PFOS (0, 1, or 10 mg/kg/day) by oral gavage in mice fed either a typical chow diet (ND) 
or a high-fat diet (HFD). Our studies show human CYP2B6 is also inducible in vivo by 
PFOS. In addition, three ND-fed hCYP2B6-Tg female mice treated with 10 mg/kg/day 
PFOS died during the exposure period. Similarly treated HFD-fed mice did not die. 
Interestingly, hCYP2B6-Tg mice retained significantly more PFOS in the serum and liver 
than Cyp2b-null mice presumably leading to the observed toxicity. Serum PFOS 
retention was significantly reduced in the HFD-fed hCYP2B6-Tg mice, which is the 
opposite trend observed in HFD-fed Cyp2b-null mice. Hepatotoxicity biomarkers, ALT 
and ALP, were higher in PFOS-treated mice and lowered by a HFD. However, PFOS 
combined with a HFD exacerbated hepatic lipid accumulation in all mice, especially in 
the hCYP2B6-Tg mice with significant disruption of key lipid metabolism genes such as 
Srebp1, Ppar, and Cpt1a. In conclusion, CYP2B6 is induced by PFOS and protects from 
PFOS-mediated steatosis in ND-fed mice; however, it’s presence increases hepatic 
triglyceride content in HFD-PFOS co-treated mice and increases toxicity in ND-fed mice. 
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Chapter I: Background 
Purpose of the Study 
The main objective of this study was to determine the role of Cytochrome P450 
2B6 (CYP2B6) in the perfluorooctanesulfonic acid (PFOS)-mediated sublethal toxicity 
and development of NAFLD, in vivo. We used two mouse models, Cyp2b9/10/13-null 
(Cyp2b-null) and a humanized CYP2B6 mouse (hCYP2B6-Tg) that lacks the murine 
hepatic Cyp2b’s but contains human CYP2B6, previously generated by Dr. Melissa 
Heintz in our laboratory. In addition, we will investigate whether a Western-like high-fat 
diet (HFD) significantly escalates PFOS-induced fatty liver disease and if CYP2B6, 
similar to Cyp2b9 and Cyp2b10, is inducible by PFOS in vivo.  
Routes of PFOS Contamination and Ingestion 
PFOS is a chemical that was produced in the manufacturing of many products 
ranging from durable stain and water repellent used on fabrics, carpets, and furniture to 
being a key chemical in aqueous film foaming form (AFFF) used in firefighting foams 
(OECD, 2006). Other consumer and industrial products include paper and cardboard food 
packaging, insecticides, electronics, paints, and non-stick cooking surfaces (EPA, 2016a). 
PFOS is manufactured through two different methods; electrochemical fluorination 
(ECF) and telomerization (EPA, 2016b). During the more common technique used to 
manufacture PFOS, ECF, both branched and linear PFOS chains are produced (30% and 
70%, respectively) whereas only linear chains are produced by telomerization. Both 
forms are able to leach into the environment and bioaccumulate (Beesoon & Martin, 
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2015; Yu et al., 2015). In 2002, the top manufacturer of PFOS, 3M, phased out its 
production in the United States (US) and the next top 8 manufacturers of PFOS in the US 
followed shortly behind (Wan et al., 2012). Although PFOS has been phased out of 
production in the US and Europe, it is still manufactured in China to produce consumer 
goods and the exact amount of PFOS produced is unknown due to a lack of regulation 
(Lim et al., 2011). PFOS is able to bioaccumulate in the environment because it is poorly 
degraded under standard environmental conditions due to its stable structure (Yamashita 
et al., 2005).  
The majority of PFOS ingestion occurs while eating contaminated food or 
drinking contaminated water; however, PFOS can also be inhaled if the soil or dust is 
contaminated (EPA, 2017). Recent testing shows that cities in the US, including 
Brunswick County (NC) and Quad Cities (IA), have higher levels of PFOS in the tap 
water (Evans et al., 2020) than the EPA health advisory risk of 70 ppt (0.07 ng/mL) 
(EPA, 2017). There are still places around the world with PFOS levels higher than 70 ppt 
in their drinking water; particularly those near a factory that produced or still produces 
fluorinated compounds such as Veneto Region, Italy as well as Jiangsu Province, China 
(Ingelido et al., 2018; Yu et al., 2015). PFOS is not only persistent in the environment but 
also persistent in humans with a half-life of approximately 5.4 years (Olsen & Zobel, 
2007). Overall, PFOS concentration detected in the environment as well as human sera 
has decreased over time as a result of being phased out of production in most countries 
but due to its stable structure, PFOS is still a concern to the environment, wildlife, and 
human health (Chang et al., 2016; Ingelido et al., 2018; Yu et al., 2015).  
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PFOS Distribution in the Human Body 
PFOS is able to bioaccumulate in the body due to its high lipophilicity and 
partition coefficients (Ahrens et al., 2011; Allendorf et al., 2019), its prevalence in the 
environment and drinking water, ability to be readily absorbed in the gastrointestinal 
tract, stability at physiological conditions in humans, and its poor clearance rate (Seacat 
et al., 2002). PFOS was detected in over 98% of human serum samples tested (Calafat et 
al., 2007). People who were occupationally exposed to PFOS had serum PFOS levels of 
approximately 1,000 ng/mL, and the general US population had serum PFOS 
concentrations ranging from 9-30 ng/mL (Frisbee et al., 2009; Kato et al., 2011; Olsen et 
al., 2012; Olsen & Zobel, 2007).  
PFOS is primarily eliminated in the urine but can be eliminated from the body in 
feces through bile mediated intestinal secretions (Chang et al., 2012; Harada et al., 2007). 
The renal clearance of PFOS in humans is extremely low due to its high renal 
reabsorption into the blood (Zhang et al., 2013). PFOS is also readily absorbed in the GI 
tract through the apical-sodium dependent bile salt transporter (ASBT) (Zhao et al., 
2017). PFOS probably enters the liver through the Na+/taurocholate cotransporting 
polypeptide (NTCP), a sodium transporter located on the sinusoidal side of hepatocytes 
and has been shown to mediate the uptake of PFOS into liver cells (Zhao et al., 2017).  
PFOS primarily binds electrostatically to albumin as well as a few other proteins 
in the blood that allows PFOS to travel readily throughout the body (Weiss et al., 2009; 
Zhang et al., 2009). PFOS is able to bind more strongly to albumin when it is a linear 
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chain and not branched (Beesoon & Martin, 2015). The two primary compartments for 
PFOS accumulation in humans are the blood and the liver (Olsen et al., 2003); however, 
PFOS has also been shown to accumulate in kidney and lung tissues with trace amounts 
in brain and bone tissue (Pérez et al., 2013).  
General PFOS Toxicity 
PFOS exposure is associated with hepatotoxicity. PFOS ingestion has been shown 
to decrease body weight and increase liver weight (Fletcher et al., 2013; Lau et al., 2007; 
Wang et al., 2014). In addition, PFOS exposure is associated with peroxisome 
proliferation, decreased serum triglyceride levels, decreased serum cholesterol levels, and 
increased expression of genes involved with fatty acid oxidation (Kim et al., 2011; Qazi 
et al., 2010; Rosen et al., 2009; Wang et al., 2014). The impact that PFOS has on fatty 
acid oxidation within the liver perturbs lipid metabolism by affecting natural biological 
processes. These data taken together show the extreme effects on the liver from PFOS 
exposure and how levels of important biomarkers, such as cholesterol and triglycerides, 
are affected by PFOS as well. It is important to continue to study PFOS to better 
understand the mechanism by which PFOS toxicity is mediated for therapeutic purposes; 
toxicity is correlated to the concentration of PFOS.  
Since PFOS is able to bioaccumulate, several studies have looked at whether 
PFOS levels in humans increase with age (Frisbee et al., 2009; Ji et al., 2012; Olsen et al., 
2003; Zeng et al., 2015). There are varying reports about the dependence of age on PFOS 
levels (Ji et al., 2012; Zeng et al., 2015) but overall increased age has been associated 
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with lower PFOS concentration (Frisbee et al., 2009; Olsen et al., 2003); possibly due to 
an increase in renal clearance as a result of less renal reabsorption (Ingelido et al., 2018). 
PFOS exposure led to an increase in renal tubular apoptosis, in mice, by inducing 
Sirt1which deacetylated p53. The deacetylation of p53 resulted in an increased 
interaction between p53 and Bax; ultimately, resulting in an increase in cytosolic 
cytochrome C and caspase 3 activation (Wen et al., 2016), possibly suggesting toxicity 
associated with prolonged PFOS exposure and supporting the increased renal clearance 
because of decreased renal reabsorption due to apoptosis theory.  
Research studies continue to find that PFOS has damaging effects on the body 
(Geng et al., 2019; Zarei et al., 2018). Although PFOS is primarily detected in the liver 
and blood, with some accumulation in the lungs and kidney, its toxicity has been 
observed throughout the human body. 
 
PFOS Effects on NAFLD and Peroxisome Proliferator-Activated Receptors  
NAFLD is a common liver disorder defined as the presence of at least 5% of the 
liver being steatotic (5% weight is lipid) (Younossi et al., 2016). Approximately 30% of 
Americans are currently suffering from it (Younossi et al., 2016). Due to the high 
prevalence of NAFLD in humans, there are many in vivo studies to determine the 
different mechanisms involved with this disease (Bagley et al., 2017; George et al., 
2003). There are a variety of different genes associated with the progression of NAFLD, 
such as CYP4A14 and CYP2E1, and the prevention of NAFLD, such as CYP3A4 and 
murine Cyp2b9&10, that are regulated by ligand activated transcription factors including 
  6  
 
 
PPARs, CAR, and PXR (Cobbina & Akhlaghi, 2017; Heintz et al., 2019; Zhang et al., 
2017). PFOS has been shown to promote NAFLD through direct interaction with 
peroxisome proliferators in addition to independently of peroxisome proliferation; the 
exact mechanisms of PFOS toxicity have not fully been elucidated yet (Andersen et al., 
2008; Jin et al., 2020; Kersten & Stienstra, 2017; Rosen et al., 2010; Skat-Rørdam et al., 
2019). 
Peroxisome proliferator-activated receptors (PPARs), alpha (-) and gamma (-), 
are transcription factors that regulate gene expression in response to endogenous and 
exogenous ligands including fatty acids, eicosanoids, pyrethrins, and trichloroethylene 
(Corton, 2008; Liss & Finck, 2017; Takeuchi et al., 2006). PFOS has been shown to 
activate peroxisome proliferators (Shipley et al., 2004; Wolf et al., 2012; Zhang et al., 
2014). PPAR is expressed in human liver and highly expressed in murine liver and is 
responsible for regulating genes involved in fatty acid beta-oxidation and plays a vital 
role in energy homeostasis (Corton et al., 2014; Klaunig et al., 2012; Peraza et al., 2006; 
Rosen et al., 2010). PFOS activates mouse and human PPAR, more so mouse, in a 
COS-1 cell based luciferase reporter trans-activation assay (Shipley et al., 2004; Wolf et 
al., 2012). The downstream response of activating PPAR by PFOS was evaluated using 
FAO-PPAR cells and an upregulation in genes involved in fatty acid oxidation, 
including peroxisomal 3-ketoacyl-CoA thiolase, peroxisomal bifunctional enzyme, acyl-
CoA oxidase, and urate oxidase was observed (Shipley et al., 2004). Using wild type 
(WT) and PPAR-null mice, PFOS was shown to be a weak activator of PPAR in vivo 
and that PFOS is able to elicit hepatotoxicity independent of PPAR (Rosen et al., 2010). 
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These data show that PFOS can activate PPAR to some extent; however, it is probably 
not the predominant mechanism of PFOS induced steatosis. 
PPAR has been a therapeutic target for diabetes and NAFLD; rosiglitazone, a 
potent PPAR inducer, showed significant decreases in hepatotoxicity biomarkers and 
increased sensitivity to insulin in patients with diabetes but elicited unwanted side effects 
such as obesity (Liss & Finck, 2017; Neuschwander-Tetri et al., 2003). PPAR is 
expressed in many tissues, such as liver, heart, and most abundantly in adipose tissue, and 
plays a role in lipid metabolism, adipocyte differentiation, and inflammation (Zhang et 
al., 2014). HepG2 cells, a human liver cancer cell line, transfected with human PPAR 
showed that PFOS is a weak agonist of PPAR in vitro; however, PFOS induces the 
disruption of lipid homeostasis and inflammation by activating PPAR (Zhang et al., 
2014). PFOS exposure showed little to no change in Ppar gene expression in animals 
(Fang et al., 2012; Wen et al., 2016). Since PFOS is a weak PPAR agonist in vitro and 
does not elicit much change in Ppar expression in vivo, PPAR mediated PFOS toxicity 
is probably less of an issue than PPAR. 
 
PFOS Effects on Lipid Metabolism and Mitochondrial Function 
PFOS is a hydrophobic compound that has a polar head and nonpolar tail, 
resembling a biological fatty acid (Fletcher et al., 2013). The structure of PFOS allows it 
to bind the hepatocyte nuclear factor 4-alpha (HNF4) which is a nuclear transcription 
factor responsible for metabolic regulation, including glucose and lipid metabolism, and 
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hepatocyte differentiation (Beggs et al., 2016; Bonzo et al., 2012). The ability of PFOS to 
directly bind HNF4 was shown using in silico docking simulations (Beggs et al., 2016) 
supporting the possibility of direct interaction of PFOS and HNF4. HNF4 is highly 
expressed in the liver and is repressed by PFOS, resulting in the downregulation of genes 
involved in lipid metabolism and markers of hepatocellular differentiation, such as 
cholesterol 7-hydroxylase (CYP7A1) and alcohol dehydrogenase 1-beta (ADH1B), 
respectively (Beggs et al., 2016). The activation of HNF4 in mice has been shown to 
upregulate genes involved in mitochondrial -oxidation, ketogenesis, and lipid transport 
protecting against NAFLD progression (Huang et al., 2020). It is important to note that 
HNF4a also transcriptionally regulates PPAR which could explain the observed PFOS 
hepatotoxicity in PPAR-null mice (Beggs et al., 2016; Rosen et al., 2010). These data 
suggests a decrease in lipid metabolism due to the repression of HNF4 expression by 
PFOS, resulting in increased hepatic steatosis and the progression of NAFLD.  
PFOS has been shown to decrease serum glucose, triglycerides, and cholesterol in 
mice (Bijland et al., 2011; Wang et al., 2014) but increase hepatic triglyceride 
accumulation by downregulating enzymes, such as carnitine palmitoyl transferase 1A 
(CPT1A), in addition to decreasing LDL/VLDL production (Cheng et al., 2016; 
Eisenberg, 1990). CPT1A and CYP7A1 are key enzymes in lipid metabolism and are 
induced by a HFD but down-regulated by PFOS (Wang et al., 2014). The observed 
down-regulation by PFOS decreased the amount of fatty acids transported into the 
mitochondria as well as decrease the amount of fatty acids converted into cholesterol. 
Very low density lipids (VLDL) are cholesterol that transport fatty acids out of the liver 
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to peripheral tissues to help prevent the buildup of hepatic triglycerides (Eisenberg, 1990) 
and prevent NAFLD progression. PFOS has been shown to decrease VLDL in the liver 
resulting in an increase in retention of fatty acids ultimately leading to steatosis and 
hepatomegaly (Bijland et al., 2011; Cui et al., 2017). The inhibition of CPT1A indicates a 
decrease in the transport of fatty acids into the mitochondria for mitochondrial -
oxidation resulting in fatty acid accumulation within the liver (Cheng et al., 2016). 
PFOS was found to have the highest inhibitory effect on mitochondrial function 
of all fluorinated compounds tested on isolated rat liver mitochondria (Wallace et al., 
2013). The respiratory inhibition was a result of PFOS altering the mitochondrial 
membrane fluidity (Wallace et al., 2013). The increase in mitochondrial membrane 
fluidity as a result of PFOS exposure is similar to how cholesterol increases 
mitochondrial membrane fluidity by inserting itself into the lipid bilayer (Matyszewska et 
al., 2008; Wallace et al., 2013). PFOS exposure, both in mice and zebrafish, significantly 
decreases mitochondrial -oxidation and increases peroxisomal -oxidation within the 
liver as well as decreases LDL/VLDL production; ultimately, resulting in poor fatty acid 
utilization and distribution, leading to hepatic steatosis (Cheng et al., 2016; Cui et al., 
2017; Wan et al., 2012). 
 
PFOS Immunotoxicity 
PFOS has been associated with suppressed immune function in vitro and in vivo 
(Brieger et al., 2011; Peden-Adams et al., 2008; Qazi et al., 2009; Zheng et al., 2009). 
Human leukocytes treated with PFOS and stimulated with lipopolysaccharide (LPS)-
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initiated a reduction in the number of natural killer (NK) cells, an important part of the 
innate immune system, produced as well as a decrease in the amount of tumor necrosis 
factor-alpha (TNF-), a pro-inflammatory cytokine, in vitro (Brieger et al., 2011; 
Trinchieri, 1989). Lower levels of PFOS exposure (≤ 5 mg/kg/day) have been shown to 
not affect NK cell counts in mice (Peden-Adams et al., 2007); however, elevated levels of 
PFOS ( 20 mg/kg/day) tend to decrease the amount of NK cells in mice (Zheng et al., 
2009).  
High levels of PFOS (20 mg/kg/day) exposure over a short period of time (7-10 
days) caused a decrease in the spleen and thymus weight of mice (Qazi et al., 2009; 
Zheng et al., 2009); however, no change was observed in these immune organs in mice 
treated with ≤ 5 mg/kg/day PFOS (Peden-Adams et al., 2008). One group showed that 
PFOS suppressed humoral immunity and identified B-cells or antigen presenting cells as 
the potential target for PFOS mediated immunotoxicity (Peden-Adams et al., 2008). The 
data suggests that the immune system is suppressed by PFOS at higher concentrations 
and thus the immune system cannot appropriately respond to foreign harmful cells when 
exposed to increased amounts of PFOS. 
 
PFOS Neurotoxicity 
PFOS interfered with the cell viability and cell differentiation of the neurotypical 
cell line, PC12 (Slotkin et al., 2008). 250 mol of PFOS decreased cell viability and 
increased the number of cells differentiating into the acetylcholine neurotransmitter 
phenotype instead of the dopamine neurotransmitter phenotype (Slotkin et al., 2008). 
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Increased acetylcholine neurotransmitters has been shown to affect the cholinergic 
system resulting in a hypoactive response to nicotine in mice (Johansson et al., 2008).  
PFOS causes neurological issues such as memory, learning, and motor behavior 
disabilities potentially due to increased apoptosis in the brain (Long et al., 2013). Mice 
exposed to 2.15 or 10 mg/kg/day PFOS took significantly longer to escape the Morris 
water maze test and spent less time in the target quadrant indicating an issue with 
learning and motor behavior (Long et al., 2013). These mice also had a significant 
increase in the number of apoptotic cells within their hippocampi compared to the control 
mice (0 mg/kg/day PFOS). In the mice treated with 10 mg/kg/day PFOS, dopamine and 
one metabolite of dopamine, dihydrophenolacetic acid (DOPAC), levels were 
significantly decreased whereas glutamate levels increased indicating brain damage 
(Long et al., 2013). Dopamine plays a role in locomotor activity (Hall et al., 2014) and a 
surge in glutamate levels is detrimental to nearby neurons as high levels of glutamate can 
impair learning and memory (Greene & Greenamyre, 1996). Taken together, these data 
suggest that PFOS perturbs neurotransmitter levels and can cause brain damage affecting 
memory, learning, and motor behavior.  
 
PFOS Reproductive and Developmental Toxicity 
PFOS causes reproductive and developmental effects in many studies (Lau et al., 
2003; Thibodeaux et al., 2003; Yahia et al., 2008). PFOS (20 mg/kg/day) significantly 
decreased thyroxine levels in mice (T4; important for growth and metabolism); while 
triiodothyronine (T3) and thyroid stimulating hormone (TSH) were unaffected 
  12  
 
 
(Thibodeaux et al., 2003). PFOS (10 or 15 mg/kg/day) lead to extreme birth defects such 
as reduced fetal birth weights, cleft palate, ventricular septal deficit, and an enlargement 
of the right atrium. No pups survived 24 hours from the mothers treated with 15 or 20 
mg/kg/day PFOS and only 50% of the pups whose mothers were treated with 10 
mg/kg/day PFOS survived longer than 24 hours. All of the pups whose mothers were 
treated with 5 mg/kg/day PFOS or more and survived experienced a significant delay in 
opening their eyes as well as a significant increase in liver weights (Lau et al., 2003). 
Another study found similar developmental PFOS toxicity (Yahia et al., 2008). All pups 
from mice treated with 20 mg/kg/day PFOS were born pale, weak, inactive, and died 
within 24 hours and 45% of pups from mice treated with 10 mg/kg/day PFOS died within 
24 hours. These data provide strong support that in utero exposure to PFOS has extreme 
birth defects and severely compromises the pup’s survival. 
 
Cytochrome P450 2B6 
CYPs are a super family of metabolic enzymes responsible for metabolizing 
xenobiotics and endogenous compounds. CYP families 1-3 are responsible for 90% of all 
phase l metabolism of xenobiotics (Wang & Tompkins, 2008). CYP3A4 is the most 
abundant CYP in human livers and is the most well-known metabolizer of xenobiotics 
and has been estimated to be responsible for about 50% of all drug metabolism (Achour 
et al., 2014; Wolbold et al., 2003). Historically CYP2B6 was thought to play a minor role 
in drug metabolism and has recently been identified as making up 6-10% of CYP 
expression in the liver and responsible for approximately 8% of all drug metabolism 
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(Desta & Flockhart, 2017; Nolan et al., 2006). Humans only have the one CYP2B gene, 
CYP2B6, which is predominantly found in the liver and is responsible for metabolizing 
environmental chemicals, steroids, and polyunsaturated fatty acids (PUFA’s) (Nelson et 
al., 2004). CYP2B6 is regulated by Pregnane X Receptor (PXR), Constitutive Androstane 
Receptor (CAR), and FoxA2; all crucial xenobiotic or metabolic transcription factors 
(Hashita et al., 2008; Kretschmer & Baldwin, 2005). In models where CAR and FoxA2 
are inhibited or knocked out the mice become obese or develop fatty liver disease 
(Bochkis et al., 2013; Dong et al., 2009). PFOS moderately activates CAR (Rosen et al., 
2010) and there are many genes induced by PFOS that are known to be regulated by PXR 
suggesting that PFOS may activate PXR in addition to CAR (Bijland et al., 2011). 
CYP2B6 has been shown to be induced by PFOS in vitro but not in vivo (Rosen et al., 
2013).  
Mice have 5 Cyp2b members (Cyp2b9/10/13/19/23), where Cyp2b23 is only 
expressed in the liver of younger mice, Cyp2b19 is primarily expressed in the skin, and 
Cyp2b9/10/13 are expressed primarily in the liver (Finger et al., 2011). Interestingly, 
male Cyp2b9/10/13-null mice are diet induced obese (Heintz et al., 2019) as are humans 
exposed to PFOS (Liu et al., 2018). PFOS also induces fatty liver disease in mice while 
increasing murine Cyp2b members such as Cyp2b9 and Cyp2b10 (Das et al., 2017). 
Furthermore, Cyp2b9 is the most induced gene in several HFD studies (Heintz et al., 
2019; Hoek-van den Hil et al., 2015; Leung et al., 2016) and Cyp2b10 is highly induced 
in several recent PFOS studies (Martell et al., 2018; Rooney et al., 2019; Rosen et al., 
2010). These data show that murine hepatic Cyp2b’s respond to factors that progress the 
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development of NAFLD, including PFOS, and begs the question whether or not human 
CYP2B6 plays a protective role in the progression of PFOS mediated NAFLD and if a 
HFD exacerbates NAFLD progression.  
 
Mouse Models 
A Cyp2b9/10/13 null mouse model was generated by removing a 287 kb section 
of murine chromosome 7 containing three hepatic Cyp2b genes to aid in determining the 
role of murine hepatic Cyp2b’s in xenobiotic and endobiotic metabolism (Kumar et al., 
2017). This was done by using the Crispr-Cas9 system and 3 short guided RNAs specific 
for each murine hepatic Cyp2b. Through non homologous end joining one of the resultant 
mice lacked Cyp2b9/10/13 (Kumar et al., 2017). The mouse lacking the murine hepatic 
Cyp2b’s was crossed with a CYP2B6/2A13/2F1-Tg mouse generated by Dr. Xinxin Ding 
and containing the promoter regions of each CYP (Wei et al., 2012) to yield a mouse that 
possessed the human CYP2B6 gene and its regulatory regions while completely lacking 
the primarily hepatic Cyp2b’s; Cyp2b9/10/13 (Heintz, 2020; Wei et al., 2012). The 
purpose of producing this mouse was to reduce the uncertainty associated with 
extrapolating data from murine to human CYPs. This will allow the human CYP2B6 
gene to be studied in vivo and provide a better understanding of the role that CYP2B6 
plays in obesity, fatty acid metabolism, and xenobiotic metabolism.  
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Hypothesis and Aims 
We hypothesize that humanized CYP2B6 mice will be less susceptible to PFOS 
toxicity, including PFOS-mediated NAFLD in comparison to Cyp2b-null mice regardless 
of diet. Furthermore, PFOS will prove to be a potent CYP2B6 inducer in vivo.  
 
Aim 1: To test whether CYP2B6 mitigates PFOS-induced NAFLD and whether a 
HFD exacerbates the development of PFOS-induced NAFLD. 
Experimental Design 
110 mice between the ages of 10-12 weeks were split into 19 different groups 
based on their gender, genotype, diet, and PFOS exposure. The mice were either exposed 
to 0 mg/kg/day, 1 mg/kg/day, or 10 mg/kg/day PFOS (0-, 1-, or 10-PFOS) via oral 
gavage every morning for 21 days. After the three-week exposure, the mice were 
euthanized and liver, serum, white adipose tissue (WAT), brown adipose tissue (BAT), 
kidneys, testes, brain, lower trapezius muscle, and gastrocnemius muscle were harvested 
and weighed. The tissues were snap frozen before being stored at -80oC.  
To evaluate the role CYP2B6 plays in PFOS mediated NAFLD we first examined 
whether CYP2B6 was inducible by PFOS or not. Microsomes and RNA were isolated 
from liver tissue and CYP2B6 protein and gene expression was determined via Western 
blot and qPCR. Oil Red O staining was conducted and analyzed to visualize the 
progression of NAFLD. Relative hepatic expression of genes related to NAFLD, 
peroxisome proliferation (Ppar and Cyp4a14) and inflammation (Cd68), were measured 
using qPCR (Chistiakov et al., 2017; Skat-Rørdam et al., 2019; Zhang et al., 2017). 
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Important serum biomarkers, including ALT, ALP, glucose, cholesterol, triglycerides, 
and LDH, were analyzed to determine the different tissues and metabolic processes 
affected by PFOS.  
Based on the literature, it was expected to see an increased expression of genes 
that promote NAFLD (Cyp4a14) and a decrease in expression of genes that repress 
NAFLD (Ppar). An increase in NAFLD was expected in groups treated with PFOS and 
potentiated by a HFD. 
 
Aim 2: To compare PFOS’s effects on lipid metabolism in CYP2B6 and Cyp2b-null 
mice. 
To further investigate the effect of PFOS on lipid metabolism more qPCR was 
performed. Relative hepatic gene expression of enzymes and proteins involved in lipid 
metabolism (Cpt1a, Hmgcr, and Srebp1) were quantified by qPCR (Jiang et al., 2018; 
Ruiz et al., 2014; Schlaepfer & Joshi, 2020). It is expected to see a down regulation in 
expression of these genes as a result of PFOS.  
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Abstract 
Perfluorooctanesulfonic acid (PFOS) is a persistent, toxic fluorosurfactant foam used 
stain repellents, firefighting foams, textiles, and other industrial products. Human 
CYP2B6 is predominantly expressed in the liver and responsible for metabolizing xeno- 
and endobiotics. CYP2B is induced by PFOS and high-fat diets in rodents and therefore it 
was hypothesized that CYP2B contributed to PFOS-induced steatosis. Cyp2b-9/10/13-
null (Cyp2b-null) and humanized CYP2B6-Tg (hCYP2B6-Tg) mice were treated with 
PFOS (0, 1, or 10 mg/kg/day) by oral gavage in mice fed either a typical chow diet (ND) 
or a high-fat diet (HFD). Our studies show human CYP2B6 is also inducible in vivo by 
PFOS. In addition, three ND-fed hCYP2B6-Tg female mice treated with 10 mg/kg/day 
PFOS died during the exposure period. Similarly treated HFD-fed mice did not die. 
Interestingly, hCYP2B6-Tg mice retained significantly more PFOS in the serum and liver 
than Cyp2b-null mice presumably leading to the observed toxicity. Serum PFOS 
retention was significantly reduced in the HFD-fed hCYP2B6-Tg mice, which is the 
opposite trend observed in HFD-fed Cyp2b-null mice. Hepatotoxicity biomarkers, ALT 
and ALP, were higher in PFOS-treated mice and lowered by a HFD. However, PFOS 
combined with a HFD exacerbated hepatic lipid accumulation in all mice, especially in 
the hCYP2B6-Tg mice with significant disruption of key lipid metabolism genes such as 
Srebp1, Ppar, and Cpt1a. In conclusion, CYP2B6 is induced by PFOS and protects from 
PFOS-mediated steatosis in ND-fed mice; however, it’s presence increases hepatic 
triglyceride content in HFD-PFOS co-treated mice and increases toxicity in ND-fed mice.  
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Introduction 
Perflurooctanesulfonic acid (PFOS) is a chemical used in stain repellents, varnishes, 
cleaning products, semiconductors, and firefighting foams (OECD, 2006). PFOS was 
phased out of production in the United States (US) and Europe for most uses; however, it 
is still manufactured in China. PFOS is persistent and bioaccumulates in the environment 
(Yamashita et al., 2005), and therefore is found in surface, ground, and drinking water 
(Chang et al., 2016; EPA, 2017; OECD, 2006). PFOS is also persistent in humans with a 
half-life of approximately 5.4 years (Olsen & Zobel, 2007), and in turn is present in the 
majority of US citizens where obesity related illnesses are the leading causes of death 
(Gleason et al., 2015; Heron, 2019). It is detected in the blood of 98% of Americans with 
serum PFOS concentrations of approximately 1,000 ng/mL in occupationally exposed 
personnel and 9-30 ng/mL in the general US population (Frisbee et al., 2009; Gleason et 
al., 2015; Kato et al., 2011; Olsen et al., 2012; Olsen & Zobel, 2007).  
 
PFOS leads to a decrease in body weight and an increase in liver weight in part due to 
non-alcoholic fatty liver disease (NAFLD) (Fletcher et al., 2013; Lau et al., 2007; Wang 
et al., 2014), while simultaneously decreasing serum glucose, triglycerides, and 
cholesterol in mice (Bijland et al., 2011; Wang et al., 2014). NAFLD is defined by the 
accumulation of hepatic fats that account for at least 5% of the liver weight, and can 
progress to non-alcoholic steatohepatitis (NASH) and ultimately lead to the development 
of fibrosis and cirrhosis (Cobbina & Akhlaghi, 2017; Zhang et al., 2017). PFOS has been 
shown to induce hepatic steatosis by interfering with key processes such as lipid 
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synthesis, lipid hepatic export process, and -oxidation (Cheng et al., 2016). Reduced 
mitochondrial -oxidation would and suppression of LDL/VLDL transport would lead to 
excess fatty acids in the liver (Cheng et al., 2016); resulting in a buildup of hepatic 
triglycerides.  
 
CYPs, especially within families 1-3, are a superfamily of metabolic enzymes responsible 
for metabolizing xenobiotics and endogenous compounds (Kretschmer & Baldwin, 
2005). Perturbations in several CYPs have been shown to increase NAFLD, including 
Cyp3a members, Cyp2b members, Cyp2j members, and Cyp2e1 (Heintz et al., 2019; 
Kumar et al., 2018; Olona et al., 2018; Seth et al., 2014). CYP2B6 is the only CYP2B 
member in humans. CYP2B6 metabolizes a large array of pharmaceuticals, 
environmental chemicals, steroids, and polyunsaturated fatty acids (PUFA’s) (Desta & 
Flockhart, 2017; Hodgson & Rose, 2007; Wang & Tompkins, 2008), including 
pesticides, polyaromatic hydrocarbons, and industrial chemicals such as chlorpyrifos, 
benzo(a)pyrene, and styrene, respectively (Hodgson & Rose, 2007; Kim et al., 1997; 
Tang et al., 2001). CYP2B6 is regulated by the pregnane X-receptor (PXR), constitutive 
androstane receptor (CAR), and forkhead box A2 (FoxA2); all crucial xenobiotic and/or 
metabolic transcription factors (Hashita et al., 2008; Kretschmer & Baldwin, 2005).  
 
PFOS moderately activates CAR and PXR in mice (Rosen et al., 2010) and induces 
murine Cyp2b9 and 10 (Das et al., 2017). It also activates peroxisome proliferator 
activated receptors (PPARs) that plays vital roles in the regulation of lipid metabolism, 
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distribution, energy homeostasis, and adipocyte maturation (Corton et al., 2014; Huck et 
al., 2018; Klaunig et al., 2012; Xu et al., 2016). PFOS induces human CYP2B6 in vitro 
but this has not been verified in vivo (Rosen et al., 2013).  
 
Our laboratory has recently developed a Cyp2b-null mouse lacking the primarily hepatic 
Cyp2b9, 10, and 13 genes found in tandem repeat (Heintz et al., 2019; Kumar et al., 
2017). In addition, we recently developed a humanized CYP2B6-Tg (hCYP2B6-Tg) 
mouse on the Cyp2b-null background to reduce some of the uncertainty when 
extrapolating from mice to humans. The CYP2B6 mouse will allow the human CYP2B6 
gene to be studied in vivo and provide a better understanding of the role it plays in PFOS 
toxicity and the co-treatment of PFOS and a HFD. Cyp2b9/10/13-null mice are diet-
induced obese in males (Heintz et al., 2019); however, these effects are not observed in 
females and in fact Cyp2b-null females are protected from NASH (Heintz et al., 2020). 
Cyp2b9 and Cyp2b10 are highly inducible in the liver by high-fat diets, and in several 
cases Cyp2b9 was the most highly induced gene (Heintz et al., 2019; Hoek-van den Hil et 
al., 2015; Leung et al., 2016). Whether CYP2B6 is induced by a HFD is not known.  
 
Because murine Cyp2b members are highly induced by PFOS, the purpose of this study 
was to determine if human CYP2B6 is induced by PFOS and/or a HFD, to test whether 
CYP2B6 protects from the development of PFOS-mediated NAFLD, and determine 
whether the combination of a HFD and PFOS (similar to the condition of many global 
and US citizens) increases the hepatotoxicity of PFOS and escalates PFOS-induced 
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NAFLD. To determine these aims, we compared male and female mice treated with 0, 1, 
or 10 mg/kg/day PFOS in both Cyp2b-9/10/13-null (Cyp2b-null) and hCYP2B6-Tg mice. 
This study will help identify CYP2B6’s and a HFD’s role in PFOS-mediated 
hepatotoxicity and NAFLD. 
 
Materials and Methods 
Animals and Diet: All studies were reviewed and approved by Clemson University’s 
Institution Animal Care and Use Committee (IACUC). Housing and studies were 
performed in a controlled environment with a temperature of 24  2oC, 60-70% relative 
humidity, and a 12:12 h light:dark cycle. C57BL/6J-Cyp2b10em1(Del(7Cyp2b10-
Cyp2b9))Fatso/Mmnc mice, often called Cyp2b9/10/13-null or abbreviated as Cyp2b-null 
mice, lack the murine genes Cyp2b9, Cyp2b10, and Cyp2b13 on a C57Bl/6J (B6) 
background. Cyp2b-null mice were developed using Crispr/Cas9 to delete a 287 kb 
region of chromosome 7 (Kumar et al., 2017). Humanized CYP2B6/2A13/2F1-transgenic 
mice on the Cyp2b-null background were generated by breeding CYP2B6/2A13/2F1-
transgenic mice generated previously (Wei et al., 2012) to our Cyp2b-null mice in order 
to generate Cyp2b-null mice containing the human BAC clone of CYP2B6/2A13/2F1 to 
what we abbreviate to hCYP2B6-Tg mice (Heintz, 2020).  
 
Mice were genotyped from extracted genomic DNA isolated from tails using the 
QuantaBio (Beverly, MA USA) AccuStart II Mouse Genotyping Kit according to the 
manufacturer’s instructions. Each mouse was genotyped to confirm that the 
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Cyp2b9/10/13 cluster on murine chromosome 7 was deleted using the F2/R2 primer set: 
(F2: 5’-gccagggtcagcatattcaccaa-3’/ R2: 5’-gcacagacatcatgaggttctggtg-3’; 59oC) to 
confirm the deletion followed by a Cyp2b13 specific primer set (F1: 5’-
cagactcttgttagaccggaccat-3’ / R1: 5’-ccccaaggaataaaattctacatg-3’; 59oC) to ensure the 
mice were not heterozygous (Kumar et al., 2017). hCYP2B6-2A13-Tg primer set (F1: 5’-
cctggacagatgcctttaactccg-3’ / R1: 5’-tggctttgcacctgcctgact-3’; 63oC) then confirmed the 
presence of the human BAC clone containing CYP2B6 and the CYP2B6/2A13/2F1 P450 
cluster on human chromosome 19 (Wei et al., 2012). 
 
 
Table 1: Description of the different treatment groups by gender, diet and 
genotype with replicate numbers in parenthesis. 
Males Females 
Normal Diet High Fat Diet Normal Diet High Fat Diet 
Cyp2b-
null 
hCYP2B6 
Cyp2b-
null 
hCYP2B6 
Cyp2b-
null 
hCYP2B6 
Cyp2b-
null 
hCYP2B6 
0 
mg/kg 
PFOS 
(n = 6) 
0 mg/kg 
PFOS (n 
= 7) 
  
0 mg/kg 
PFOS (n 
= 5) 
0 
mg/kg 
PFOS 
(n = 5) 
0 mg/kg 
PFOS (n 
= 7) 
0 
mg/kg 
PFOS 
(n = 5) 
0 mg/kg 
PFOS (n = 6) 
1 
mg/kg 
PFOS 
(n = 6) 
1 mg/kg 
PFOS (n 
= 7) 
  
  
1 
mg/kg 
PFOS 
(n = 5) 
1 mg/kg 
PFOS (n 
= 7) 
  
1 mg/kg 
PFOS (n = 5) 
  
10 
mg/kg 
PFOS 
(n = 5) 
10 
mg/kg 
PFOS (n 
= 7) 
  
10 
mg/kg 
PFOS (n 
= 5) 
10 
mg/kg 
PFOS 
(n = 5) 
10 
mg/kg 
PFOS (n 
= 7) 
10 
mg/kg 
PFOS 
(n = 5) 
10 mg/kg 
PFOS (n = 5) 
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Mice, 10-12 weeks old, were separated into 19 different groups based on their genotype, 
PFOS (Sigma-Aldrich, St. Louis, MO, USA) dose, gender, and diet (Table 1). PFOS, 
dissolved in a solution of water and 0.5% Tween 20, was administered by gavage each 
morning for three weeks. Mice were either fed a normal diet (ND; 2018S-Envigo Teklad 
Diet, Madison, WI) consisting of 18% kcal of fat, or a high-fat diet (HFD; Envigo, 
TD.06414 Adjusted calorie diet) consisting of 60.3% kcal of fat. Water was provided ad 
libitum. Male Cyp2b-null male mice were not provided a HFD in conjunction with PFOS 
because fewer Cyp2b-null male pups were born than female pups during this round of 
breeding.  
 
Necropsy: Mice were weighed prior to euthanasia. Euthanasia was performed by heart 
puncture to collect blood while under 3% isoflurane anesthesia followed by CO2 
asphyxiation. Whole blood was kept at room temperature for 30 minutes to allow for 
clotting and then centrifuged at 6,000 rpm for 10 minutes to collect serum. Liver and 
white adipose tissue (WAT) were harvested and weighed. Liver was diced into several 
pieces for lipid sampling, RNA extraction, protein preparation, and histology preparation. 
Samples were snap frozen in liquid nitrogen prior to storage at -80oC.  
 
Serum Lipids and Liver Cholesterol Screening: Serum alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, direct 
bilirubin, blood urea nitrogen (BUN), cholesterol, creatine kinase (CK), creatinine, 
gamma-glutamyl transferase (GGT), glucose, lactate dehydrogenase (LDH), calcium, 
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magnesium, phosphorous, albumin, total protein, triglycerides, and total carbon dioxide 
(CO2) were measured using a Beckmann-Coulter AU480 analyzer with the appropriate 
Beckmann-Coulter kits according to the manufacturer’s instructions (Heintz et al., 2019). 
Serum HDL and LDL/VLDL cholesterol was determined using the HDL and LDL/VLDL 
Colorimetric Quantitation Assay from Sigma Aldrich (St. Louis, MO) according to the 
manufacturer’s instructions. Total liver cholesterol was determined using the Cholesterol/ 
Cholesteryl Ester Quantitation Assay Kit from Abcam (Cambridge, MA USA) according 
to the manufacturer’s instructions. Each measured serum and liver parameters were 
statistically compared across groups using GraphPad Prism 7.0 (La Jolla, CA USA). 
Principle component analysis (PCA) was performed using RStudio to associate serum 
and liver parameters with PFOS dose, diet, or genotype.  
 
Principal Component Analysis (PCA) biplot:  
Two PCA biplots were generated, male and female, to compare differences in groups 
based on diet, PFOS, and genotype using 19 different parameters. The PCA biplots were 
generated using the data visualization package, ggplot2, in RStudio. Treatment groups 
were color coded and overlaid on each of the plots, respectively. A normal data ellipse 
was drawn for each group, a scale factor of 2 was applied to observations, and a scale 
factor of 2 was applied to variables. An aspect ratio of 1 was used to make the plots 
square. The x-axis (PC1) and y-axis (PC2) show the percent of explained variability 
amongst the data.  
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Oil Red O Staining: Liver samples (n=3) from each group were sectioned and stained 
with Oil Red O according to standard protocol (Dong et al., 2009). Stained slides were 
imaged (400X magnification) on a Leica Acquire Light Microscope and analyzed using 
ImageJ Fiji Particle Analysis to quantify the lipids and triglycerides in the liver 
(Schindelin et al., 2012). Briefly, the scale bar was set to 0.05 mm and the threshold color 
was set to red, with red pass selected and green/blue pass deselected. The wavelength was 
set to 120-255 and the range of the size (mm2) was set to 0.00001-infinity for all images 
(Heintz et al., 2020).  
 
RNA Quantification and quantitative Real-time Polymerase Chain Reaction (qPCR): 
RNA was isolated in TRIzol (Invitrogen, Carlsbad, CA USA) according to the 
manufacturer’s instructions, initially quantified on a NanoDrop, and stored at -80oC. 
DNA contamination was eliminated with the Turbo DNA-Free Kit (Invitrogen, Carlsbad, 
CA). RNA was then re-quantified with the Qubit RNA BR Assay (Invitrogen, Carlsbad, 
CA) using the Qubit 4 Fluorometer (Invitrogen, USA) for improved accuracy. qPCR was 
performed using primers specific for Srebp1, Cpt1a, CYP2B6, Ppar, Cd68, Cyp2a5, 
Cyp4a14, Hmgcr, CYP2A13, 18S and Gapdh (Supplemental Table 1). 1 L of cDNA 
was briefly mixed and incubated with 12.5 L RT2 SYBR Green (Qiagen Frederick, MD 
USA), 9.5 L Millipore water, 1 L of the forward and reverse primers (25 L per well). 
All plates were heated to 95oC for 1 minute followed by 50 cycles of denaturation at 95oC 
for 30 seconds, annealing for 30 seconds (temperature varied for each primer; 
Supplemental Table 1), and elongation for 45 seconds at 72oC. To determine the melt 
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curve, samples were heated to 76.5oC for 5 seconds and then 95oC for 5 minutes. 
Efficiency of the reaction was determined with a standard curve performed in triplicate 
with a mix of samples diluted from 1:1 - 1:1024. Samples were diluted 1:20 and 
fluorescence measured using a Bio-Rad CFX96 Real-Time System. Gene expression was 
quantified and normalized to the geometric means of 18S and Gapdh as the housekeepers 
using the inverted Muller’s equation (Muller et al., 2002; Roling et al., 2004).  
 
Western Blot: Livers were individually homogenized with a Dounce Homogenizer and 
microsomes isolated by differential centrifugation (Van Der Hoeven & Coon, 1974). 
Protein concentrations were determined using the Bradford Protein Assay according to 
the manufacturer’s instructions (Bio-Rad, Hercules, CA, USA). Western blots were 
performed to determine CYP2B6 and CYP2A protein expression with 25 g of 
microsomal protein. Briefly, samples were separated via gel electrophoresis, transferred 
to a Bio-Rad PVDF (Hercules, CA USA), and quantified using antibodies (diluted 
1:1000) specific to CYP2B6 (Chemicon International, Temecula, CA USA), CYP2A 
(Thermo-Fisher Scientific, Rockford, IL USA), with β-actin (Sigma Aldrich, St. Louis, 
MO) as the reference gene (Hernandez et al., 2006). An alkaline phosphatase conjugated 
goat anti-rabbit IgG (Bio-Rad) secondary antibody (diluted 1:500) was used to identify 
the CYP2B6 and CYP2A primary antibodies. Goat anti-mouse IgG (Bio-Rad) secondary 
antibody (diluted 1:500) was used to recognize β-actin primary antibody. Individual 
proteins were detected with the chemiluminescent Immun-Star AP detection kits from 
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Bio-Rad, and band intensities were quantified on a Bio-Rad ChemiDoc Imaging System 
with iLab. 
 
Vivid (Blue) CYP2B6 Enzyme Inhibition Assay: PFOS inhibition of CYP2B6 activity was 
determined and compared to nonylphenol using the Vivid CYP2B6 Blue Screening Kit 
from Life Technologies (Carlsbad, CA USA). 
 
Liver PFOS Extractions: Liver PFOS was extracted using a slightly modified previously 
published method (Chang et al., 2017). Frozen liver tissues (~50 mg) was homogenized 
in 2 mL Omni Hard Tissue Homogenizing tubes containing 1.4 mm ceramic beads, with 
400 µL cold, deionized water spiked with a fixed amount of a stable isotope-labeled 
internal standard (13C4-PFOS, Wellington Laboratories, Ontario, Canada, Product code: 
MPFOS). Using an Omni Bead Ruptor Elite (Omni International, Kennesaw, GA), the 
mixture was homogenized for 30 seconds at 4 m/s. 250 µL of homogenate was digested 
overnight at room temperature in 10% 1N KOH. 100 μL of digested homogenate was 
further treated with 100 μL of 2N HCl, 500 μL 1N formic acid, 500 μL of saturated 
ammonium sulfate, and 5 mL methyl tert-butyl ether (MTBE). The solution was mixed 
on a shaker (20-30 min at room temperature). The organic and aqueous layers were 
separated by centrifugation (2500 × g, 5 min), and an exact volume of MTBE (4.5 mL) 
was removed from the solution. The top organic layer was subsequently transferred to a 
new tube and evaporated. The resulting sample was reconstituted with 20 mL of 
acetonitrile and water (1:1) prior to LC-MS/MS analysis.  
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Serum PFOS Extraction: Serum collected at necropsy was prepared according to methods 
described by Hansen (Hansen et al., 2001). Briefly, 20 µL of sera, 2 μL of isotope-labeled 
internal standard (13C4-PFOS, Wellington Laboratories, Ontario, Canada, Product code: 
MPFOS), 200 µL of 0.5M tetrabutylammonium bisulfate (TBA; adjusted to pH 10), and 
400 µL of 0.25M sodium carbonate were added to a 15-mL polypropylene tube, and 
thoroughly mixed. 5 mL of MTBE was added to the solution, and the mixture was placed 
on a shaker for 20-30 min at room temperature. The organic and aqueous layers were 
separated by centrifugation (2500 × g, 5 min), and an exact volume of MTBE (4.5 mL) 
was removed from the solution. The top organic layer was subsequently transferred to a 
new tube and evaporated overnight. The resulting sample was reconstituted with 20 mL 
of acetonitrile and water (1:1) prior to LC-MS/MS analysis 
 
PFOS Quantification by LC-MS/MS: Liver and serum samples were vortexed for 30 s and 
passed through a 0.2 µm polyethersulfone membrane syringe filter (MDI Membrane 
Technologies, Harrisburg, PA) into an autosampler vial. Ultra-fast liquid chromatography 
(UFLC) was performed on a SHIMADZU Prominence UFLC system consisting of three 
LC-20AD pumps, a DGU-20A degassing unit, SIL-20AC autosampler, CTO-20AC 
column oven and CBM-20A communication bus module (Columbia, MD). 
Chromatographic separation was performed on a Waters XBridge® C18 column (100 
mm X 4.6 mm i.d., 5 μm, Milford, MA). The mobile phase consisted of 0.1% (v/v) 
formic acid/water (A) and 0.1% (v/v) formic acid/acetonitrile (B) with a gradient elution 
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of 70% of B increased to 90% of B over 8 min; at 8 min the gradient was revered to 
original conditions. The column temperature was 40°C, flow rate was 0.6000 mL/min, 
and the injection volume was 10.00 μL. Mass spectrometry was performed on the 
QTRAP 4500 system coupled with an electrospray ionization (ESI) interface (AB Sciex, 
Framingham, MA). Nitrogen was used in all cases. The parameters were optimized as 
follows: negative ionization, IonSpray voltage, -4500; nebulizer gas, 40; auxiliary heater 
gas, 45; curtain gas, 20; turbo gas temperature, 400; declustering potential, -60; entrance 
potential, -10; collision energy, -122; collision cell exit potential, -15. The samples were 
analyzed in MRM (Multiple Reaction Monitoring) mode. The MRM ion pair used for 
PFOS quantification was 498.9/79.8 and compared to a standard curve prepared in either 
liver or serum matrix to account for matrix effects. The data were acquired using Analyst 
1.6.3 software and processed using MultiQuant 3.0.1 software. 
 
Tests of Significance: Tests of significance were performed using GraphPad Prism 
software 7.0 & 8.0 (LaJolla, CA USA). Student’s t-tests were performed when comparing 
two groups, and one-way ANOVAs followed by Fisher’s LSD as the post-hoc test were 
performed when comparing more than two groups. A p-value < 0.05 was considered 
significantly different.  
 
Results 
PFOS toxicity and effects on tissue, and body mass: Greater toxicity in the ND-fed 
hCYP2B6-Tg female mice given 10 mg/kg PFOS (10-PFOS) was observed. Of the 110 
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mice in the study, only three mice, all female treated with 10-PFOS and fed a ND, died 
during the 21-day exposure. Two died on day 20 and the third died on day 21 at the onset 
of the necropsies. Neither males nor HFD-fed females provided 10-PFOS died indicating 
increased sensitivity in females compared to males and protection from lethality provided 
by a HFD (Fig. 1).  
Table 2: Body weights, Liver weights, and WAT weights of Male mice. 
Diet Genotype 
PFOS 
(mg/kg) 
Body Weight (g) Liver Weight (g) WAT Weight (g) 
Normal 
Diet 
(ND) 
Cyp2b-
null 
0 22.58±0.54p**g** 0.958±0.024p*** 0.335±0.014 
1 23.77±0.70g*** 1.372±0.038g*** 0.388±0.045 
10 18.11±0.37p**g 1.820±0.12p***b 0.0382±0.025p 
hCYP2B6 
0 23.20±0.55p**g**d** 0.927±0.022p***g 0.426±0.058pd*** 
1 23.52±0.50g*** 1.350±0.027g*** 0.310±0.025 
10 18.51±0.81p**g* 2.004±0.067p***gd*b 0.0714±0.022p 
High 
Fat 
Diet 
(HFD) 
0 27.55±1.87p***gd** 1.066±0.10p*** 
1.358±0.290p***gd**
* 
10 20.29±0.70p***g** 
2.250±0.070p***g**d
* 
0.260±0.051p*** 
Data represented as mean +/- SEM. All units are expressed in g. Statistical significance was 
determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test.  
‘p’ indicates difference between PFOS concentration 
‘g’ indicates difference between gender (see Table 3) 
‘d’ indicates difference between diet 
‘b’ indicates difference between genotype 
Letter with no asterisk indicates p < 0.05, * indicates p < 0.01, ** indicates p < 0.001, and 
*** indicates p < 0.0001. 
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PFOS increased liver mass and decreased body mass in a dose-dependent manner, 
especially at 10 mg/kg PFOS. Weight loss can be in part attributed to the complete lack 
of white adipose tissue in these mice (Table 2 & 3). The addition of a HFD increased 
Table 3: Body weights, Liver weights, and WAT weights of Female mice 
Diet Genotype 
PFOS 
(mg/kg) 
Body Weight 
(g) 
Liver Weight 
(g) WAT Weight (g) 
Normal 
Diet 
(ND) 
Cyp2b-
null 
0 
18.37±0.34p*g**
d** 
0.79±0.042p*** 0.212±0.036d** 
1 18.15±0.65g*** 
0.956±0.035g**
* 
0.156±0.037 
10 15.15±0.78p*g 
1.69±0.039p***d
* 
0.024±0.016 
hCYP2B
6 
0 
18.42±0.23p*g**
d*** 
0.73±0.028p***g
d** 
0.1986±0.022d*** 
1 
17.38±0.23g***d
*** 
0.8543±0.060g*
**d*** 
0.1471±0.014d*** 
10 14.68±0.29p*d* 1.763±0.20p***g 0.025±0.025 
High 
Fat 
Diet 
(HFD) 
Cyp2b-
null 
0 
22.76±0.93p***d
** 
0.902±0.036p**
* 
0.868±0.15p***d** 
10 16.09±0.69p*** 
1.954±0.105p**
*d* 
0.178±0.030p*** 
hCYP2B
6 
0 
24.87±1.12p***g
d*** 
1.028±0.033p**
*d** 
1.002±0.24p***gd*** 
1 23.32±1.63d*** 
1.232±0.074d**
* 
0.988±0.29d*** 
10 
16.15±0.27p***g
** 
1.916±0.030p**
*g** 
0.15±0.021p*** 
Data represented as mean +/- SEM. All units are expressed in g. Statistical significance 
was determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test.  
‘p’ indicates difference between PFOS concentration 
‘g’ indicates difference between gender (see Table 2) 
‘d’ indicates difference between diet 
‘b’ indicates difference between genotype 
Letter with no asterisk indicates p < 0.05, * indicates p < 0.01, ** indicates p < 0.001, 
*** indicates p < 0.0001. 
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liver, body, and WAT weights but was negated by PFOS. Furthermore, the mean liver 
weight of hCYP2B6-Tg male mice fed a ND and treated with 10-PFOS was 10% heavier 
than their Cyp2b-null counterparts (p < 0.0001) (Table 2), suggesting increased hepatic 
sensitivity to PFOS in the humanized mice. 
 
CYP2B6: PFOS is a strong inhibitor of CYP2B6 in vitro with an IC50 of 165 nM (95% 
CI: 104 - 255 nM) (Fig. 2). PFOS shows similar, but slightly lower, potency than 
nonylphenol (IC50 = 77.3 nM; 95% CI: 57.5 – 103 nM), which was used as a positive 
control (Acevedo et al., 2005), indicating that PFOS interacts with CYP2B6 and may act 
as an inhibitor in vivo.  
 
Previous research has indicated that PFOS is a potent murine Cyp2b inducer (Cheng & 
Klaassen, 2012; Das et al., 2017; Rosen et al., 2017). PFOS has been shown to induce 
CYP2B6 in vitro (Rosen et al., 2013); however whether it is an inducer of human 
CYP2B6 in vivo is in question. This transgenic model contains the CAR and FoxA2 
upstream promoter and enhancer regions of CYP2B6 (Wei et al., 2012). CYP2B6 gene 
expression was significantly induced by PFOS in both male (7.8X) and female (163X) 
mice fed a ND as determined by qPCR (Fig. 3ab). HFD exacerbated CYP2B6 gene 
expression only in female mice (2.7X) compared to their ND counterparts (Fig. 3b). 
Western blots confirmed dose-dependent CYP2B6 induction at the protein level in males 
and females, including HFD-mediated CYP2B6 induction in the females (Fig. 3ab) 
although induction was much lower than measured by qPCR. In summary, PFOS induces 
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CYP2B6 in a hCYP2B6-Tg model that contains the CYP2B6 human promoter and 
enhancer regions (Wei et al., 2012).  
 
CYP2A13 along with CYP2F1 were both a part of the BAC clone used to generate the 
original CYP2B6/2A13/2F1-Tg mouse. Both CYP2A13 and CYP2F1 are predominantly 
expressed in the respiratory tract and previous research indicates they are not expressed 
in the liver (Wei et al., 2012). qPCR was performed to confirm human CYP2A13 is not 
expressed in liver because members of the CYP2A subfamily are known to metabolize 
xenobiotics and endogenous lipids (Lu & Cederbaum, 2006). Human CYP2A13 
expression was not detected in the liver by qPCR (data not shown), but genomic 
CYP2A13 is detected from tail snips demonstrating that our assay worked and there was 
no CYP2A13 hepatic expression. Murine Cyp2a5 was also measured because it is the 
predominant CYP2A enzyme in adult murine liver, Cyp2a5 and several other Cyp2a 
members were induced in Cyp2b-null mice or a HFD in comparison to WT mice, and it is 
orthologous to the human CYP2A6 hepatic enzyme (Abu-Bakar et al., 2012; Heintz et 
al., 2019). Cyp2a5 gene expression was increased by 5.3X and 6.3X in ND-fed Cyp2b-
null male and female mice, respectively, treated with 10-PFOS compared to Cyp2b-null 
controls (0-PFOS), with a 2.7X increase in HFD-fed Cyp2b-null mice provided 10-PFOS 
compared to HFD-fed 0-PFOS Cyp2b-null mice as well. Cyp2a5 gene expression 
increased 1.9X and 2.2X in ND- and HFD-fed hCYP2B6-Tg male mice treated with 10-
PFOS compared to their 0-PFOS counterparts (Fig. 3cd). Cyp2a5 gene expression was 
not induced by 10-PFOS in hCYP2B6-Tg female mice. In contrast, PFOS repressed male 
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protein expression of CYP2A with slight induction in the Cyp2b-null females (Fig. 3cd). 
In summary, human CYP2A13 is not expressed in murine livers. Murine Cyp2a5 
compensates for a lack of Cyp2b expression in null mice, is responsive to PFOS by 
qPCR, strongly repressed by PFOS in males, and repressed by a HFD in females.  
 
Retention of PFOS in hCYP2B6 mice: Serum and liver PFOS concentrations were 
determined by LC-MS/MS analysis and demonstrated concentration-dependent increases. 
hCYP2B6-Tg mice showed significantly increased PFOS retention compared to Cyp2b-
null mice in males and females treated with 10-PFOS and fed a ND (Fig. 4ab). The 
average serum PFOS was 1.46X greater in ND-fed hCYP2B6-Tg male mice than ND-fed 
Cyp2b-null male mice, and 1.74X greater in ND-fed hCYP2B6-Tg female mice than 
identically treated Cyp2b-null female mice (Fig. 4a). When treated with a HFD, 
hCYP2B6-Tg mice showed a significant decrease in PFOS retention, unlike the Cyp2b-
null mice. In humanized mice, the average serum PFOS level was 1.63X lower in HFD-
fed male mice than their ND-fed counterparts and 1.13X lower in HFD-fed female mice 
than their ND-fed counterparts. However, in Cyp2b-null female mice, the average serum 
PFOS level was 1.62X greater in the HFD-fed mice than ND-fed mice at 10 mg/kg/day 
(Fig. 4a).  
 
Liver PFOS retention followed a similar pattern to serum PFOS retention; greater PFOS 
retention in ND-fed hCYP2B6-Tg male and female mice compared to their Cyp2b-null 
counterparts (1.14X and 1.39X, respectively) (Fig. 4b). A HFD increased PFOS retention 
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within the liver of all groups with the most significant increase in the Cyp2b-null female 
mice compared to their ND-fed counterparts (1.3X) (Fig. 4b). This data suggests that a 
HFD may play a protective role in PFOS toxicity in hCYP2B6-Tg mice but not Cyp2b-
null mice. Further, the greater PFOS retention measured in humanized mice was 
unexpected and may explain the decreased survival in the hCYP2B6-Tg female mice fed 
a ND (Fig. 1).  
 
Serum markers of liver toxicity are increased by PFOS and reduced by a HFD: Alkaline 
phosphatase (ALP) and alanine aminotransferase (ALT), which are indicative of liver 
damage, were both significantly increased by PFOS in a dose-dependent manner (Fig. 
5ab). Genotype only had an effect on ALT levels in 10-PFOS treated hCYP2B6-Tg 
males compared to Cyp2b-null males where the presence of CYP2B6 was protective 
from liver damage (Fig. 5b) despite greater measured PFOS concentrations (Fig. 4). 
Interestingly, ALP levels were significantly lower in HFD-fed mice and mean serum 
ALT levels significantly decreased in HFD-fed mice treated with 10-PFOS compared to 
their ND-fed counterparts (Fig. 5). These data indicates that a HFD decreases PFOS-
mediated hepatotoxicity with CYP2B6 having a potentially protective role in males 
despite greater PFOS retention. 
 
PCA biplot investigating associations between key serum parameters in different 
treatment groups: Other serum parameters are also perturbed by PFOS, diet or genotype, 
including glucose, triglycerides, total cholesterol, LDL/VLDL and HDL, and LDH 
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(Supplementary Figures 1-5). Therefore, PCA biplots examining associations between 
19 different parameters were performed to compare relationships among treatment groups 
in males and females. In both males and females, the biplots account for approximately 
60% of the variation amongst the data. The male mice treated with 0-PFOS or 1-PFOS 
grouped together skewing towards triglycerides (TAG) and glucose (GLU) (Fig. 6). The 
ND-fed male mice treated with 10-PFOS grouped towards biomarkers indicative of 
hepatotoxicity, ALT and ALP (bottom right of plot). The HFD-fed hCYP2B6-Tg male 
mice treated with 10-PFOS grouped towards to the 0-PFOS or 1-PFOS treated groups 
when compared to their 10-PFOS counterparts, consistent with data that a HFD is playing 
a protective role against PFOS toxicity in hCYP2B6-Tg male mice (Fig. 6).  
 
The female mice treated with 0-PFOS or 1-PFOS also grouped together with TAG and 
GLU. HFD-fed Cyp2b-null female mice, regardless of PFOS concentration, showed lots 
of variation with several mice weighted toward cardiovascular toxicity biomarkers, 
cholesterol and lactate dehydrogenase (top left of plot), suggesting that Cyp2b-null 
female mice may be at an increased risk of cardiovascular disease when fed a HFD (Fig. 
7). All of the female mice treated with 10-PFOS, regardless of diet, grouped separately 
from the female mice treated with 0-PFOS or 1-PFOS and towards biomarkers indicative 
of liver damage such as ALT and ALP (bottom left of plot) (Fig. 7) with surprisingly 
little variation between genotypes given the greater PFOS concentrations and toxicity 
observed in the hCYP2B-Tg females treated with 10-PFOS. Of course, serum was not 
collected from the mice that died and therefore their data is not reflected in the PCA 
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biplots. However, parameters associated with toxicity are reduced in female HFD-fed 
Cyp2b-null mice compared to ND-fed Cyp2b-null female mice (Fig. 7).  
 
Hepatic triglycerides: Oil Red O staining indicates a significant increase in liver 
triglyceride concentrations in the ND-fed male and female Cyp2b-null mice treated with 
1-PFOS compared to their hCYP2B6-Tg counterparts (10.33X and 50.4X, respectively) 
(Fig. 8), indicating a prominent role for CYP2B6 in protection from PFOS-mediated fatty 
liver when fed a ND. A HFD significantly increased liver triglyceride concentrations in 
every group except hCYP2B6-Tg male mice treated with 0-PFOS. In addition, NAFLD 
progression was exacerbated in all mice exposed to PFOS (Fig. 8). hCYP2B6-Tg female 
mice fed a HFD and treated with 10-PFOS had 1.41X greater triglyceride accumulation 
in the liver compared to their Cyp2b-null counterpart (Fig. 8h). In summary, ND-fed 
Cyp2b-null mice had a greater accumulation of hepatic triglycerides than their 
hCYP2B6-Tg counterparts treated with 1-PFOS; however, HFD-fed Cyp2b-null mice had 
significantly less liver triglycerides than their hCYP2B6-Tg counterparts treated with 10-
PFOS (Fig. 8), indicating the progression of NAFLD is slowed by the presence of 
CYP2B6 in a ND but exacerbated by a HFD. 
 
qPCR: qPCR was performed to identify expression changes in genes associated with 
peroxisome proliferation (Ppar; Cyp4a14) (Wafer et al., 2017; Zhang et al., 2017), 
inflammation (Cd68) (Chistiakov et al., 2017), and lipid metabolism (Hmgcr; Cpt1a; 
Srebp1) (Jiang et al., 2018; Ruiz et al., 2014; Schlaepfer & Joshi, 2020). Ppar 
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expression was significantly repressed in all PFOS-treated male mice and hCYP2B6-Tg 
female mice (Fig. 9a), suggesting that PFOS is interfering with adipogenesis. 
Interestingly, Ppar was significantly increased in females by a HFD, but only in 
hCYP2B6-Tg mice; not Cyp2b-null mice. Cyp4a14 gene expression was increased in all 
groups treated with 10-PFOS except ND-fed Cyp2b-null male mice and HFD-fed 
hCYP2B6-Tg female mice. Cyp4a14 expression was significantly induced by the 
combination of PFOS and a HFD in hCYP2B6-Tg male mice (21.5X) and Cyp2b-null 
female mice (3.9X). However, PFOS-treated hCYP2B6-Tg female mice showed 
significantly less induction than correspondingly treated Cyp2b-null mice (Fig. 9b). 
Since Cyp4a14 is regulated by Ppar and has been associated with NAFLD (Zhang et 
al., 2017), this data indicates that PFOS activates Ppar and promotes the progression of 
NAFLD, which is corroborated by the Oil Red O stains. Cd68 gene expression was 
inhibited in all of the humanized mice treated with 10-PFOS except for the HFD-fed 
hCYP2B6-Tg male mice (Fig. 9c). PFOS had no significant effect on Cd68 gene 
expression in Cyp2b-null mice; suggesting that although PFOS is hepatotoxic, there may 
be less inflammatory signaling in the liver when exposed to PFOS in the presence of the 
human CYP2B6 gene or untreated hCYP2B6-Tg mice are more prone to inflammation.  
 
Hmgcr gene expression in 10-PFOS-treated hCYP2B6-Tg mice was inhibited by 60% in 
HFD-fed hCYP2B6-Tg male mice, 93% in ND-fed hCYP2B6-Tg female mice, and 88% 
in HFD-fed hCYP2B6-Tg female mice (Fig. 10a). These results suggest that PFOS may 
inhibit the metabolism of cholesterol in the liver of humanized mice potentially leading to 
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greater NAFLD (Jiang et al., 2018) consistent with HFD-PFOS cotreatments. Cpt1a gene 
expression was lower in all groups treated with 10-PFOS except for the HFD-fed Cyp2b-
null female mice (Fig. 10b). Cpt1a gene expression was significantly repressed in all 
humanized groups except HFD-fed male mice potentially because they show greater 
constitutive expression. Because Cpt1a is essential for fatty acid mitochondrial transport 
and oxidation (Schlaepfer & Joshi, 2020), this data suggests that PFOS inhibits lipid 
metabolism and the humanized mice are more affected, consistent with the increased 
NAFLD progression observed in the humanized mice. Humanized male and female 
Srebp1 gene expression was induced by a HFD (2.3X and 2.1X, respectively) and 
negated by 10-PFOS (1.8X and 1.6X, respectively) (Fig. 10c). Srebp1 was also down-
regulated by PFOS, but in a different manner depending on the genotype in females. This 
data is consistent with Srebp1’s role in lipogenesis, TAG synthesis, and NAFLD (Ruiz et 
al., 2014), especially following a HFD and in the HFD-fed hCYP2B6-Tg mice whom are 
the most sensitive to NAFLD. Srebp1 was also associated with loss of NAFLD in ND-fed 
PFOS treated mice.  
 
Discussion 
The purposes of this study were to determine if PFOS induces human CYP2B6, and test 
whether CYP2B6 protects from PFOS toxicity and NAFLD. We were able to address 
these questions and examine the adverse effects of co-treatment of PFOS and a HFD. 
First, CYP2B6 is inducible by PFOS. Surprisingly, female humanized mice are 
significantly more sensitive to PFOS toxicity than their Cyp2b-null counterparts, 
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probably due to an increase in PFOS retention in hCYP2B6-Tg mice. However, sublethal 
measurements, such as NAFLD, were more sensitive in Cyp2b-null mice than hCYP2B6-
Tg mice unless the mice were treated with a HFD in which case hCYP2B6-Tg female 
mice were more sensitive to NAFLD as demonstrated by Oil Red O and several 
biomarkers of NAFLD.  
 
Toxicity was significantly greater in hCYP2B6-Tg females than Cyp2b-null females. 
Three ND-fed hCYP2B6-Tg female mice exposed to 10-PFOS died and these were the 
only mice to die during the 3 week exposure period (Fig. 1) clearly demonstrating the 
sensitivity of ND-fed hCYP2B6-Tg mice to PFOS. Interestingly, their HFD-fed 
counterparts survived (Fig. 1), indicating that a HFD was protective from lethality 
probably due to the increased adiposity. The increased toxicity in the hCYP2B6-Tg mice 
is most likely due to increased PFOS retention and the subsequent effects caused by 
greater PFOS. LC-MS/MS analysis showed that serum and liver PFOS was significantly 
greater in the hCYP2B6-Tg mice compared to their counterparts when fed a ND; more so 
in female mice (174% and 139%, respectively) than male mice (146% and 114%, 
respectively). HFD significantly decreased serum PFOS concentrations in all hCYP2B6-
Tg mice. In contrast, a HFD led to a significant increase in serum and liver PFOS 
retention in female Cyp2b-null mice compared to their ND-fed counterparts, nevertheless 
hCYP2B6-Tg mice still had greater liver PFOS retention.  
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PFOS induces human CYP2B6 in male and female mice (Fig. 3ab). These results 
confirm that CYP2B6 is inducible by PFOS in a dose dependent manner similar to 
murine Cyp2b10 (Rosen et al., 2010). A HFD exacerbated CYP2B6 induction in females 
(Fig. 3b). HFD induced murine Cyp2b9 and Cyp2b10 in previous studies (Heintz et al., 
2019; Hoek-van den Hil et al., 2015; Leung et al., 2016), potentially due to activation of 
CAR by PUFAs (Finn et al., 2009), or activation of FoxA2 due to insulin resistance 
(Wolfrum et al., 2004), glucagon or glucocorticoid signaling (Zhang et al., 2005). 
CYP2B6 protein induction was moderate in comparison to changes in RNA levels and it 
is unlikely that CYP2B6 directly regulates PFOS retention.  
 
Hepatic CYP2A gene and protein expression was determined to ensure that one of the 
human genes from the original construct, CYP2A13 (Wei et al., 2012), was not being 
expressed in the liver. qPCR confirmed that CYP2A13 is not expressed in the liver in 
hCYP2B6-Tg mice confirming previous results (Wei et al., 2012). Cyp2a5 is the 
predominant hepatic CYP2A member in adult mice and has been shown to be female 
predominant (Lu & Cederbaum, 2006; Poça et al., 2017). Cyp2a5 gene expression 
increased significantly in all of the Cyp2b-null groups (Fig. 3cd), potentially as a 
compensatory mechanism (Kumar et al., 2017). However, CYP2A protein expression 
was repressed in male mice exposed to PFOS regardless of genotype and in Cyp2b-null 
female mice (Fig. 3cd). Based on these results, neither CYP2A13 or other CYP2A 
members are playing roles in the increased PFOS retention and toxicity observed in 
hCYP2B6-Tg mice.  
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PFOS exhibited severe toxicity on several different tissues and metabolic pathways, 
which was evident by biomarkers from the serum panel. Hepatotoxicity was observed in 
the groups exposed to 10-PFOS based on the significantly elevated ALP and ALT levels 
(Fig. 5). However, increased toxicity caused by higher PFOS serum and liver 
concentrations did not always manifest themselves as higher serum markers of tissue 
toxicity. ALT and ALP levels indicate greater liver toxicity in ND-fed mice than HFD-
fed mice, consistent with lower PFOS concentrations in the HFD-fed mice. However, 
hCYP2B6-Tg mice showed no difference in ALP and ND-fed male hCYP2B6-Tg had 
lower ALT levels than similarly fed Cyp2b-null mice (Fig. 5). PCA indicates a clearly 
protective effect of a HFD from PFOS toxicity in male mice, but not female mice (Fig. 6-
7). This protective effect was highly pronounced in the hCYP2B6-Tg male mice as this 
group was found between the 0- and 1-PFOS groups and the other 10-PFOS groups.  
 
PCA also indicates an increase in markers indicative of poor cardiovascular health such 
as cholesterol, triglycerides, LDH, and LDL in Cyp2b-null mice compared to hCYP2B6 
mice. This may be due to differences in fatty acid metabolism as CYP2B6 and other 
CYPs are involved in PUFA metabolism (Bishop-Bailey et al., 2014; Heintz et al., 2019; 
Nelson et al., 2004). There is overlap between the genotypes in the PCA plot; however, 
lack of Cyp2b in both males and females pushes the groups towards these adverse 
cardiovascular parameters and in some cases it is clear that the combination of a Cyp2b-
null genotype and a HFD are deleterious to some parameters such as LDH and 
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cholesterol (Supplementary Figures 3-4). Last, serum glucose and triglyceride levels 
were significantly lower in groups treated with 10-PFOS compared to 0-PFOS suggesting 
PFOS interferes with gluconeogenesis and fatty acid esterification (Das et al., 2017; 
Hagenaars et al., 2008) (Supplementary Figure 1-2).  
 
PFOS increases NAFLD. Previous work has demonstrated that male Cyp2b-null mice are 
more susceptible to NAFLD than wildtype mice (Heintz et al., 2019), and ND-fed 
Cyp2b-null male and female mice were more susceptible to 1-PFOS mediated NAFLD 
than hCYP2B6-Tg mice. However, the combination of PFOS and a HFD potentiated 
NAFLD, especially in hCYP2B6-Tg mice in comparison to Cyp2b-null mice (Fig. 8); 
therefore this result appears surprising. Recent results investigating the effects of a 16-
week HFD on hCYP2B6-Tg mice show that CYP2B6 is an anti-obesity CYP; however, it 
increases NAFLD while protecting male mice from diabetes (Heintz, 2020). Female 
hCYP2B6-Tg mice were more susceptible to the HFD-PFOS co-treatment than Cyp2b-
null mice. New data suggests that CYP2B6 is not protective from NAFLD and possibly 
increases NAFLD susceptibility through increased production of oxylipins (Deol et al., 
2017; Heintz, 2020). These results suggest a complicated role of CYP2B6 in metabolism 
of PUFAs only during a HFD in which hepatic PUFA concentrations are high.  
 
NAFLD progression is associated with decreases in Cpt1a (Fig. 10), a key gene involved 
in mitochondrial fatty acid uptake prior to -oxidation in the liver (Schlaepfer & Joshi, 
2020). There was a significant decrease of relative Cpt1a gene expression in HFD-fed 
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hCYP2B6-Tg mice treated with 10-PFOS compared to their 0-PFOS counterparts. 
LDL/VLDL levels in the serum were also significantly lower in PFOS treated groups 
(Supplementary Figure 5). A decrease in Cpt1a gene expression and oxidation coupled 
with lower LDL production and release may explain the exacerbated increase in hepatic 
triglyceride content in the liver. These findings support other studies that have suggested 
PFOS induced steatosis by inhibiting mitochondrial -oxidation and decreasing LDL 
content that, normally, would help transport triglycerides out of the liver (Cheng et al., 
2016).  
 
Srebp1, Ppar, and to a lesser extent Cd68 all followed similar gene expression profiles 
following HFD or PFOS treatments with increased expression in HFD-fed hCYP2B6-Tg 
mice in comparison to HFD-fed Cyp2b-null mice (Fig. 9-10). Srebp1 is a key regulator of 
lipogenesis and therefore it is not surprising that it is associated with NAFLD (Moslehi & 
Hamidi-Zad, 2018). Srebp1 also regulates Ppar (Fajas et al., 1999) and Cd68 expression 
(Jump et al., 2013). Hmgcr, the rate determining step in cholesterol biosynthesis (Jiang et 
al., 2018), expression was slighting higher in hCYP2B6-Tg mice and repressed by PFOS 
which is consistent with the liver and serum cholesterol data (Supplementary Figures 
3,5). The greater expression of these genes in the hCYP2B6-Tg mice while fed a HFD 
may explain their sensitivity to NAFLD.  
 
PPAR and PPAR are important in maintaining energy homeostasis and lipid 
metabolism (Corton et al., 2014; Klaunig et al., 2012; Peraza et al., 2006; Rosen et al., 
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2010). Ppar is found in most tissues and is responsible for adipocyte differentiation and 
plays a role in lipid metabolism (Wafer et al., 2017; Zhang et al., 2014). Ppar gene 
expression was significantly repressed by PFOS suggesting the inhibition or inactivation 
of Ppar by PFOS. Ppar regulates a wide variety of genes including certain CYPs such 
as Cyp4a14 and Cpt1a that are associated with NAFLD but overall Ppar activation is 
associated with preventing NAFLD (Patsouris et al., 2006; Zhang et al., 2017). Cyp4a14 
levels were increased in groups treated with 10-PFOS and exacerbated by a HFD 
suggesting the activation of Ppar by PFOS and diet. Interestingly, Cpt1a expression 
increased with diet but decreased with PFOS; Cyp4a14 was repressed by the presence of 
CYP2B6 in HFD-fed mice and induced by PFOS with the exception of Cyp2b-null males 
(Fig. 9-10). The inhibition of Ppar, activation of Cyp4a14, and inhibition of Cpt1a is 
consistent with data that PFOS promotes NAFLD. Further, these results support the Oil 
Red O analysis that the HFD-fed hCYP2B6-Tg mice exposed to 10-PFOS were further 
along in NAFLD progression. 
 
Fatty acids such as alpha linolenic acid (ALA) and linoleic acid (LA) are known 
activators of Ppar (Huang & Chen, 2017; Kliewer et al., 1997) and there are several 
fatty acid metabolites that are known ligands of Ppar (Straus et al., 2000). The oxylipins 
produced from fatty acid metabolism by CYP2B6 could act as agonists for Ppar in 
addition to PFOS which would explain the exacerbated Cyp4a14 levels observed in HFD 
hCYP2B6-Tg male mice. PFOS has been shown to inactivate Ppar (Wen et al., 2016). 
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The current study supports these findings. Since Ppar gene expression is low in all 
groups treated with 10-PFOS.  
 
Human CYP2B6, is inducible in vivo by PFOS, associated with increased PFOS toxicity 
and NAFLD. In addition, a HFD was protective of PFOS toxicity in male and female 
hCYP2B6-Tg mice and the female Cyp2b-null mice. Cyp2b-null mice also had increased 
levels of biomarkers indicative of cardiovascular disease. The increased toxicity observed 
in the hCYP2B6-Tg mice fed a ND is most likely a result of the increased serum and 
liver PFOS retention in these mice. It is unknown why there was an increase in PFOS 
retention but it is clearly a result of the presence of the CYP2B6 gene. A HFD may have 
played a protective role in the humanized mice because CYP2B6 may have a higher 
affinity for the fats in the diet than PFOS; however, this does not explain differences in 
markers of toxicity associated with female Cyp2b-null mice as shown in the PCA plots. 
In conclusion, both CYP2B6 and a HFD effect PFOS toxicity and NAFLD with CYP2B6 
enhancing toxicity and NAFLD and a HFD exacerbating NAFLD but protecting mice 
from toxicity.  
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Figure Legends 
Fig. 1: Survival curve of female mice treated with different concentrations of PFOS 
via oral gavage. This survival curve was generated using GraphPad Prism 8. Statistical 
differences in survival were determined by Gehan-Breslow-Wilcoxon test where ** 
indicates p < 0.001 (n = 5-7). 
 
Fig. 2: Concentration-response curve for the inhibition of CYP2B6 by PFOS in 
comparison to the positive control, nonylphenol. IC50 and 95% CI values were 
determined using a sigmoidal dose response least squares fit test performed on GraphPad 
Prism 7 (n = 3). Multiple Student t-test’s were performed to determine significance 
between PFOS and Nonylphenol. * indicates a significant difference of p < 0.05.  
 
Fig. 3: CYP2B6 (A & B) and Cyp2a5 (C & D) hepatic gene and protein expression in 
male and female mice. Mice were treated as described in the materials and methods and 
CYP2B6 and Cyp2a5 induction measured by qPCR (n = 4-5) and Western blotting (n = 
2-3). Statistical significance was determined by one-way ANOVA when comparing 3 or 
more groups (qPCR) and by Student’s t-test when comparing two groups (Western blots). 
Statistical differences in qPCR were determined by One-way ANOVA where a letter 
indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** indicates p < 0.001 and a 
letter w/ *** indicates p < 0.0001. * indicates a significant difference of p < 0.05 in 
Western blots.  
 
Fig. 4: LC-MS/MS analysis of PFOS concentrations in the serum (A) and liver (B) of 
hCYP2B6 and Cyp2b-null mice. Data are presented as mean ± SEM. Statistical 
significance was determined by one-way ANOVA followed by Fisher's LSD as the post-
hoc test (n=4-5). A letter indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** 
indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Fig. 5: Serum concentration of Alkaline Phosphatase (ALP) (A) and Alanine 
Aminotransferase (ALT) (B) from PFOS-treated mice. Data are presented as 
mean ± SEM. Statistical significance was determined by one-way ANOVA followed by 
Fisher's LSD as the post-hoc test (n=5). A letter indicates a p < 0.05, letter w/ * 
indicates p < 0.01, letter w/ ** indicates p < 0.001 and a letter w/ *** indicates p < 
0.0001. 
 
Fig. 6: Principal component analysis (PCA) biplot composed of 19 different 
parameters compared across the 8 male groups. Graphical representation of 
multivariate data. Treatment groups are color coded and the group descriptions are 
overlaid on the plot.  
 
Fig. 7: Principal component analysis (PCA) biplot composed of 19 different 
parameters compared across the 11 female groups. Graphical representation of 
multivariate data. Treatment groups are color coded and the group descriptions are 
overlaid on the plot.  
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Fig. 8: Triglyceride content for M ND Cyp2b-null 0-PFOS (A), M ND hCYP2B6 0-
PFOS (B), M HFD hCYP2B6 0-PFOS (C), F ND Cyp2b-null 0-PFOS (D), F ND 
hCYP2B6 0-PFOS (E), F HFD Cyp2b-null 0-PFOS (F), F HFD hCYP2B6 0-PFOS 
(G), and quantified using Image J Fiji Particle Analysis (H). Images were taken at 
400x (0.05mm) magnification. Data are presented as mean ± SEM (n = 3). Statistical 
significance was determined by one-way ANOVA followed by Fisher's LSD as the post-
hoc test. A letter indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** 
indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Fig. 9: Changes in hepatic gene expression caused by genotype, PFOS, HFD, or a 
combination of PFOS and a HFD in male and female mice. Gene expression of Pparg 
(A), Cyp4a14 (B), and Cd68 (C) in male and female mice was determined by qPCR as 
described in Material and Methods. Data are presented as mean ± SEM (n = 4-5). 
Statistical significance was determined by one-way ANOVA followed by Fisher's LSD as 
the post-hoc test. A letter indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** 
indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Fig. 10: Changes in hepatic gene expression caused by genotype, PFOS, HFD, or a 
combination of PFOS and a HFD in male and female mice. Gene expression of 
Hmgcr (A), Cpt1a (B), and Srebp1 (C) in male and female mice was determined by 
qPCR as described in Material and Methods. Data are presented as mean ± SEM (n = 4-
5). Statistical significance was determined by one-way ANOVA followed by Fisher's 
LSD as the post-hoc test. A letter indicates a p < 0.05, letter w/ * indicates p < 0.01, letter 
w/ ** indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Supplemental Figure 1: Serum glucose levels (n = 5). A serum panel was performed as 
mentioned in the Materials and Methods and glucose levels were measured. PFOS 
decreased serum glucose. Data are presented as mean ± SEM. Statistical significance was 
determined by one-way ANOVA followed by Fisher's LSD as the post-hoc test. A letter 
indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** indicates p < 0.001 and a 
letter w/ *** indicates p < 0.0001. 
 
Supplemental Figure 2: Serum triglyceride levels (n=5). A serum panel was 
performed as mentioned in the Materials and Methods and triglyceride levels were 
measured. PFOS significantly decreases serum triglyceride levels. Data are presented as 
mean ± SEM. Statistical significance was determined by one-way ANOVA followed by 
Fisher's LSD as the post-hoc test. A letter indicates a p < 0.05, letter w/ * indicates p < 
0.01, letter w/ ** indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Supplemental Figure 3: Serum cholesterol levels (n=5). A serum panel was performed 
as mentioned in the Materials and Methods and cholesterol levels were measured. 
Increased serum cholesterol levels in the mice fed a high-fat diet with a significant 
increase in the cholesterol levels in Cyp2b-null mice fed a high-fat diet, regardless of 
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PFOS concentration, compared to their hCYP2B6 counterparts. Data are presented as 
mean ± SEM. Statistical significance was determined by one-way ANOVA followed by 
Fisher's LSD as the post-hoc test. A letter indicates a p < 0.05, letter w/ * indicates p < 
0.01, letter w/ ** indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
 
Supplemental Figure 4: Serum lactate dehydrogenase (LDH) levels (n=5). A serum 
panel was performed as mentioned in the Materials and Methods and LDH levels were 
measured. Significant increase of LDH levels in Cyp2b-null mice fed a high-fat diet 
regardless of PFOS concentration compared to their hCYP2B6 counterparts. Data are 
presented as mean ± SEM. Statistical significance was determined by one-way ANOVA 
followed by Fisher's LSD as the post-hoc test. A letter indicates a p < 0.05, and a letter w/ 
* indicates p < 0.01. 
 
Supplemental Figure 5: Serum HDL analysis (n=4). Total serum HDL cholesterol was 
determined using the HDL and LDL/VLDL Colorimetric Quantitation Assay from Sigma 
Aldrich (St. Louis, MO). The total HDL cholesterol concentrations were determined 
according to the manufacturer’s instructions. PFOS suppresses HDL levels in all mice. 
Data are presented as mean ± SEM. Statistical significance was determined by one-way 
ANOVA followed by Fisher's LSD as the post-hoc test (n=5). A letter indicates a p < 
0.05, letter w/ * indicates p < 0.01, letter w/ ** indicates p < 0.001 and a letter w/ *** 
indicates p < 0.0001. 
 
Supplemental Figure 6: Serum LDL/VLDL analysis (n=4). Total serum LDL/VLDL 
cholesterol was determined using the HDL and LDL/VLDL Colorimetric Quantitation 
Assay from Sigma Aldrich (St. Louis, MO). The total LDL/VLDL cholesterol 
concentrations were determined according to the manufacturer’s instructions. PFOS 
suppresses LDL/VLDL levels in all mice. Data are presented as mean ± SEM. Statistical 
significance was determined by one-way ANOVA followed by Fisher's LSD as the post-
hoc test (n=5). A letter indicates a p < 0.05, letter w/ * indicates p < 0.01, letter w/ ** 
indicates p < 0.001 and a letter w/ *** indicates p < 0.0001. 
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Supplemental Material 
Supplemental Table 1: qPCR primer information for genes of interest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1 
 
 
Gene Accession Number Forward Sequence Reverse Sequence Annealing Temperature (℃)
SREBP1 NM_001358315.1 5'-ACGAAGTGCACACAAAAGCA-3' 5'-GCCAAAAGACAAGGGGCTAC-3' 58
CPT1A NM_013495.2 5'-TTGATCAAGAAGTGCCGGACGAGT-3' 5'-GTCCATCATGGCCAGCACAAAGTT-3' 60
CYP2B6 KR711982.1 5'-CCATACACAGAGGCAGTCAT-3' 5'-GGTGTCAGATCGATGTCTTC-3' 54.5
CD68 NM_001291058.1 5'-CGCAGACGACAATCAACCTA-3' 5'-AGTGGCATGGTGAAGAGATG-3' 59
CYP2A5 NM_007812.4 5'-CAAAGCCAAGGAAGCAAGATG-3' 5'-AGTGGTGCTGAGTGGTAATG-3' 60
CYP4A14 NM_007822.2 5'-CCTCCTCATATTGCCCTGAATAG-3' 5'-GAGTCCATAGGCCTGAGTTATTT-3' 59
PPARG NM_001127330.2 5'-TGGGTGAAACTCTGGGAGATTC-3' 5'-AATTTCTTGTGAAGTGCTCATAGGC-3' 60.1
HMGCR NM_008255.2 5'-TTAGGCATGTGGTGGTGAAG-3' 5'-GCCAAGGAGGAGCAGAATAAA-3' 60
18S NR_003278.3 5'-ATGGCCGTTCTTAGTTGGTG-3' 5'-ATGCCAGAGTCTCGTTCGTT-3' 64
GAPDH NM_008084.3 5'-CCTTCATTGACCTCAACTA-3' 5'-CTGGAAGATGGTGATGG-3' 50
CYP2A13 NM_000766.5 5'-TCTCCCACTTCTTCCTCTGT-3' 5'-GGGAAGGAGGACAGACAATTAC-3' 59.8
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Chapter III: Summary and Conclusions 
Despite PFOS being phased out of production in the US and Europe in the early 
2000’s, it is still produced in China (Lim et al., 2011; Wan et al., 2012) and many studies 
have reported that PFOS is still prevalent within the environment due to its stable 
structure (Beesoon & Martin, 2015; Yamashita et al., 2005). It is also prevalent in the 
human body with a half-life of approximately 5.4 years due to poor metabolism and 
elimination (Olsen & Zobel, 2007; Seacat et al., 2002). PFOS concentrations are still 
above the health advisory risk of 70 ppt, set by the EPA (EPA, 2017), in places around 
the world, such as Veneto Region, Italy (Ingelido et al., 2018) and Jiangsu Province, 
China (Yu et al., 2015), as well as cities within the US, such as Brunswick County, NC 
and Quad Cities, IA (Evans et al., 2020). Due to its prevalence and toxicity, 
understanding the mode of action of PFOS is vital.  
CYP2B6 is the only CYP2B member in humans and is a known detoxification 
enzyme that is regulated by PXR, CAR, and FoxA2 in response to many endo- and 
xenobiotics as well as PUFA’s (Hashita et al., 2008; Kretschmer & Baldwin, 2005; 
Nelson et al., 2004). PFOS’s structure, a polar head and hydrophobic tail, resembles a 
biological fatty acid allowing it to perturb lipid metabolism (Fletcher et al., 2013) and 
cause an increase in hepatic triglyceride accumulation (Bijland et al., 2011; Cheng et al., 
2016; Cui et al., 2017). Using the two unique mouse models previously generated in our 
lab, Cyp2b-null and hCYP2B6-Tg (Heintz, 2020; Kumar et al., 2017), the current study is 
the first to evaluate CYP2B6, specifically, and its role in PFOS mediated NAFLD in mice 
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fed a ND. This study also examined whether or not a HFD exacerbated the progression of 
PFOS mediated NAFLD.  
Overall, this study shows that PFOS is able to significantly induce CYP2B6 in 
vivo, mice that express CYP2B6 are more sensitive to PFOS, and PFOS toxicity is 
relieved by a HFD in both genotypes; however, deleterious effects, such as elevated 
serum biomarkers indicative of cardiovascular toxicity (LDH & cholesterol), were 
observed in the Cyp2b-null mice fed a HFD.  
The only mice to die during the three week exposure period were three ND fed 
hCYP2B6-Tg female mice; however, none of their HFD-fed counterparts died. The 
observed PFOS toxicity in the hCYP2B6-Tg mice fed a ND can likely be attributed to the 
increased retention of liver and serum PFOS compared to their Cyp2b-null counterparts. 
The average serum PFOS retention was significantly reduced in hCYP2B6-Tg mice when 
fed a HFD whereas a HFD increased liver and serum PFOS retention in the Cyp2b-null 
mice. All ND-fed mice treated with 10-PFOS exhibited significantly elevated biomarkers 
indicative of liver damage, ALT & ALP; surprisingly, these elevated levels were relieved 
by a HFD in all groups. In the current study, PFOS decreased serum glucose, triglyceride, 
and cholesterol levels in all mice which is consistent with previous findings (Bijland et 
al., 2011; Wang et al., 2014).  
hCYP2B6-Tg mice had significantly elevated hepatic triglyceride levels in HFD-
PFOS co-treated groups compared to their Cyp2b-null counterparts. Initially, these Oil 
Red O results were shocking, however, recent studies have shown that CYP2B6 is not 
protective of NAFLD and may increase susceptibility by producing oxylipins that could 
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progress NAFLD (Deol et al., 2017; Heintz, 2020). qPCR was performed to determine 
the relative gene expression of certain genes related to peroxisome proliferation (Ppar, 
Cyp4a14) (Skat-Rørdam et al., 2019; Zhang et al., 2017) and lipid metabolism (Cpt1a) 
(Schlaepfer & Joshi, 2020). Ppar prevents the progression of NAFLD whereas Cyp4a14 
increases NAFLD progression (Liss & Finck, 2017; Zhang et al., 2017). PFOS 
significantly repressed Ppar gene expression in all groups except for HFD-fed Cyp2b-
null mice and increased Cyp4a14 gene expression. These data could explain the 
exacerbated levels of hepatic triglycerides in the HFD-PFOS co-treated hCYP2B6-Tg 
mice compared to their Cyp2b-null counterparts. Cpt1a, a key regulator of mitochondrial 
-oxidation (Cheng et al., 2016), expression was repressed by PFOS in hCYP2B6-Tg 
mice suggesting that PFOS inhibits mitochondrial -oxidation resulting in the 
accumulation of fatty acids within the liver of these mice. PFOS also lowered 
LDL/VLDL levels which are important in hepatic triglyceride export (Eisenberg, 1990). 
In agreement with other studies (Cheng et al., 2016; Wan et al., 2012), these findings 
suggest one way PFOS elicits hepatotoxicity is through the inhibition of mitochondrial -
oxidation and decreased hepatic triglyceride export. The observed hepatotoxicity was 
greater in hCYP2B6-Tg mice. 
While these results are interesting, more research needs to be done to determine 
why mice that express CYP2B6 are more sensitive to PFOS toxicity but appear to be 
protected by a HFD. To help understand why mice that express CYP2B6 are more 
sensitive to PFOS, more analysis of different genes related to lipid metabolism should be 
performed. The current study found that PFOS down regulates a few important genes 
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related to lipid metabolism, including Cpt1a and Srebp1 (Ruiz et al., 2014; Schlaepfer & 
Joshi, 2020), to a greater extent in the hCYP2B6-Tg mice compared to their Cyp2b-null 
counterparts. To better understand the different mechanisms of PFOS toxicity, a 
microarray analysis or RNA sequencing should be conducted to examine the 
transcriptomic response of genes, including key hepatic regulators such as HNF4 
(Beggs et al., 2016), from the liver to further analyze the effects of PFOS.  
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